March 04, 2015 – Qu Biologics
Vancouver, British Columbia – March 4, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune function in the targeted diseased organ, is pleased to announce it has been selected as the 2015 BC Growth Stage Life Sciences Company of the Year. Life Sciences BC will present the award at a ceremony to be held April 16, 2015.
Qu Biologics’ CEO Dr. Hal Gunn commented, “We are honoured to be recognized by our peers for the progress we have made in developing novel treatments that stimulate the body’s own immune system to treat cancer and other immune-related diseases such as inflammatory bowel disease. Our preclinical and compassionate use data have documented the potential of SSIs and we are looking forward to sharing results of our Crohn’s disease clinical trial at the end of the year.” He added, “We come to work with a passion for what we do and an excitement for its potential and we very much appreciate this honour.”
The Growth Stage Life Sciences Company of the Year Award is presented to an early-stage life sciences company which, although may not be nearing commercial success, has demonstrated outstanding performance and achieved significant milestones in 2014 and positioned itself well for potential future commercial success. The award is one of a few awards presented annually by Life Sciences BC to recognize individuals and companies who have made a significant contribution to research and excellence in B.C.’s life sciences industry. For more information about Life Sciences BC, visit www.lifesciencesbc.ca.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases. The company is currently recruiting participants for a placebo-controlled, randomized clinical trial in Crohn’s disease and a clinical trial in non-small cell lung cancer, and plans to initiate a trial in ulcerative colitis in Q2 2015.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com.
For more information regarding this press release, contact:
Qu Biologics Inc.
Phone: 604.734.1450 ext.41491